Flush with $15 million in new venture capital funding, Serenex said last week that it plans to hire an additional 30 scientists within a year and embark on a program to automate its platform for screening purine-binding proteins for interactions with small molecule lead compounds. The company has also signed early-stage partnerships with Pharmacia and Pfizer and is in negotiations with two “recently-merged” companies, Robert Dishman, Serenex’s CEO, told ProteoMonitor.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.